Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Amgen
This study will enroll adults with type 2 diabetes mellitus and elevated LDL-C or non-high-density lipoprotein cholesterol (non-HDL-C) levels on a stable, maximally tolerated statin dose of at least moderate-intensity at signing of the informed consent; statin therapy must remain unchanged during screening and the remainder of the study.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Male or female ≥ 18 years
Type 2 Diabetes Mellitus
Hemoglobin A1c \< 10%
Stable diabetes therapy
Must be on maximally tolerated dose of statin of at least moderate Intensity
Fasting triglycerides ≤ 600 mg/dL
Not at LDL-C or Non-HDL-C goal.
You may not be if
Moderate to severe renal dysfunction
Uncontrolled hypertension
Persistent active liver disease or hepatic dysfunction
Has taken a cholesterylester transfer protein inhibitor in the last 12 months,
Myocardial infarction, unstable angina, percutaneous coronary intervention, coronary artery bypass graft or stroke within 3 months prior to randomization
Clareo Health | Evaluation of Evolocumab (AMG 145) Efficacy in Diabetic Adults With Hypercholesterolemia/Mixed Dyslipidemia
